Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach-Reference-Cited by-同舟云学术

Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach

Published:2021-06 Issue: Volume:Volume 17 Page:669-677
ISSN:1178-203X
Container-title:Therapeutics and Clinical Risk Management
language:en
Short-container-title:TCRM

Author:

Grimaud Fabien,Penaranda Guillaume^ORCID,Stavris Chloé,Retornaz Frédérique,Brunel Véronique,Cailleres Sylvie,Pegliasco Hervé,Le Treut Jacques,Grisoni Vincent,Coquet Emilie^ORCID,Chiche Laurent^ORCID,Rognon Amélie

Publisher

Informa UK Limited

Subject

Chemical Health and Safety,Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,Safety Research,General Medicine

Reference29 articles.

1. A decade of immune-checkpoint inhibitors in cancer therapy

2. Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario

4. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

5. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dendritic Cell-Related Immune Marker CD1C for Predicting Prognosis and Immunotherapy Opportunities of Lung Adenocarcinoma Patients;Applied Biochemistry and Biotechnology;2024-06-22

2. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU;Gastroenterología y Hepatología;2024-04

3. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU;Gastroenterología y Hepatología (English Edition);2024-04

4. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU;Revista Española de Enfermedades Digestivas;2024

5. Gestion des toxicités des immunothérapies du cancer : challenges et « rechallenges » pour les (jeunes) internistes;La Revue de Médecine Interne;2024-01